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For the 24th time in a row the Interuniversity Cardiology
Institute of the Netherlands (ICIN-Netherlands Heart Institute)
and the Netherlands Society of Cardiology (NVVC)
supported the competition for the best three cardiovascular
PhD theses published in the year 2012. The dissertation prize
carries the name of one of the greatest Dutchmen in the history
of cardiovascular medicine, Willem Einthoven, who in 1902
for the first time recorded the human ECG, for which he
received the Nobel Prize in 1924.
This time the jury received a total of 34 PhD dissertations.
The jury members were very much impressed by the high
scientific quality of the PhD fellows. Based on scientific orig-
inality, the number of articles in first-rate journals, the contri-
bution as a first author (or shared first author) to the papers, and
the number of citations, the jury finally selected three nomi-
nees: Dr. A.S. Amin, (Academic Medical Centre Amsterdam),
Dr. R.J. van Bommel, (Leiden UniversityMedical Center), and
Dr. R Pisters (Maastricht University Medical Centre).
The members of the jury were: M. Alings, H.J. Crijns, J.
Deckers, W.H. van Gilst, V. Umans, and E.E. van der Wall.
The three candidates presented their PhD thesis at the
annual Spring Congress of the NVVC at the Congress
Centre De Leeuwenhorst, in Noordwijkerhout, on 4 April
2013. The ultimate winners of the first, second and third
prize were chosen by the audience. Summaries of the three
nominated PhD theses are given below.
Modifiers of phenotype in inheritable arrhythmia
syndromes
Single autosomal-dominant mutations in genes encoding for
cardiac ion channels serve as the primary genetic substrate
for inheritable arrhythmia syndromes such as the long-QT
syndrome (LQTS) and the Brugada syndrome (BrS) [1].
This discovery has been the basis for staggering numbers
of subjects and families counselled worldwide for inherit-
able arrhythmia syndromes and (prophylactically) treated
based on finding a mutation [2]. However, therapy is greatly
hampered by the growing awareness that simple carriership
of a mutation often fails to predict phenotype: many muta-
tion carriers never develop clinically relevant disease while
others experience sudden cardiac death at a young age. It is
still largely elusive what determines this variability in dis-
ease severity, where even family members with an identical
mutation still display large differences in disease severity
[1,3]. This suggests that additional factors modify the phe-
notypic manifestations of a disease-causing mutation. The
research described in this thesis aimed to uncover potential
genetic and environmental factors that, in conjunction with a
mutation, modify the phenotype in inherited arrhythmia
syndromes (Fig. 1).
Fever and exercise as modifiers of phenotype
Our clinical studies demonstrate that in patients with BrS,
linked to mutations in SCN5A (the gene encoding for the
cardiac sodium channel), fever increases the risk of cardiac
arrest due to ventricular tachycardia/fibrillation [4], and fever
and exercise, separately, aggravate the typical BrS ECG
changes (i.e., more PR and QRS widening and further right-
precordial ST segment elevation) [4–5]. Moreover, our data
suggest that timely use of antipyretics reduces the risk for
cardiac arrest during fever. Our experimental studies demon-
strate that BrS-linked SCN5A mutations impair cardiac sodi-
um channel function more severely at higher body
temperatures and at faster heart rates, thereby providing a
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molecular mechanism for the phenotype-modifying role of
fever and exercise in patients with BrS [6–7]. We also provide
clinical and experimental evidence that fever prolongs QTc
duration and triggers torsade de pointes ventricular tachycar-
dia and ventricular fibrillation in some patients with LQTS
type 2, the second most prevalent type of LQTS [8].
Fig. 1 Genetic and
environmental factors
that potentially modify the
phenotype in inherited
arrhythmia syndromes
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Single nucleotide polymorphisms as modifiers of phenotype
We show that single nucleotide polymorphisms (SNPs) in
the 3′untranslated region (3′UTR) of KCNQ1, the gene
encoding for a major cardiac potassium channel, modify
the phenotype in LQTS type 1, the most prevalent type of
LQTS [2]. MicroRNAs bind to the 3′UTR and thereby
inhibit the translation of the messenger RNA to protein
[9]. SNPs in the 3′UTR are frequent and have been proposed
to contribute to individual variation in phenotype [10].
However, clear evidence for this concept was lacking.We show
that SNPs in the 3′UTR of KCNQ1 repress translation, and
that these repressive SNPs largely determine the clinical
severity in heterozygous carriers of an LQTS-linked
KCNQ1 mutation. When the suppressive SNPs reside on
the normal KCNQ1 allele, the normal allele is repressed
and there is clear clinical manifestation of the mutation
(long QTc durations and severe symptoms). When the
suppressive SNPs reside on the mutant KCNQ1 allele, this
mutant allele is repressed and there are hardly any clinical
manifestations of the mutation [3]. Our findings suggest
that 3′UTR SNPs can alter microRNA binding and thereby
modulate clinical expression of a disease-causing mutation.
Our findings also suggest that in autosomal-dominant dis-
eases, such as LQTS and BrS, disease severity can be
modified by allelic imbalance induced by sequence varia-
tion in the 3′UTR stemming from the unaffected parent.
A.S. Amin
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Cardiac resynchronisation therapy: determinants
of patient outcome and emerging indications
In this thesis, a comprehensive analysis was performed on
the long-term effects of cardiac resynchronisation therapy
(CRT) in selected patients with heart failure.
In the last decade, CRT has evolved as a very successful
treatment strategy in selected patients with drug refractory
heart failure. Evidence of large clinical trials undeniably
established the beneficial effects of CRT in addition to optimal
medical treatment on both morbidity and mortality. These
effects include improved LV systolic function, improved clin-
ical status, improved exercise tolerance and improved quality
of life. The outcomes of these large trials resulted in the fact
that for many years, CRT has been considered a class I
indication in patients with end-stage heart failure (NYHA
class III-IV) with an LVEF ≤35 % and a QRS complex
duration ≥120 ms. Nonetheless, about 30 % of patients do
not demonstrate response and it has become clear that many
factors determine outcome in patients undergoing CRT. This
thesis demonstrated that several patient characteristics have a
strong influence on both response at 6-month follow-up and
prognosis during long-term follow-up. Most important among
these characteristics are gender, the presence of atrial fibrilla-
tion, renal failure and the presence of significant LV
dyssynchrony. In addition to these patient characteristics, the
position of the LV pacing lead in relation to the site of latest
activation and potential scar tissue may have a great influence
on outcome, especially in patients with ischaemic aetiology of
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heart failure. Integration of patient characteristics, LV lead
position with information on LV dyssynchrony and scar tissue
may help to improve patient selection and response to CRT.
As large trials continued, more evidence for the benefit of
CRT in other patient populations became available. As a
result, since 2010 CRT has also been considered a class I
indication in patients with mild symptoms of heart failure
(NYHA class II) with an LVEF ≤35 % and a QRS complex
duration ≥150 ms. It is not unlikely that the favourable
effects of CRT will be extended to other patient groups in
the coming years. These groups include asymptomatic
(NYHA class I) patients, patients with a narrowQRS complex
(<120 ms) or patients with heart failure but preserved LVEF
(≥45 %). Many clinical trials are still underway and the future
for CRT cannot be predicted at this moment. Data from this
thesis showed that CRT also seems to improve other condi-
tions frequently observed in patients with systolic heart fail-
ure. The improved LV systolic function induced by CRT
increases cerebral blood flow (which is regularly decreased
in heart failure patients). Furthermore, CRT-induced improve-
ment in LV function also results in stabilisation of renal
function, which is frequently decreased in heart failure pa-
tients. Finally, patients with severe functional MR and high
operative risk also derive benefit from CRT. In these patients,
CRT leads to a decrease in MR (Fig. 2), which in turn results
in improved prognosis. Perhaps CRT may 1 day be used as an
effective treatment strategy in these patient groups.
R.J. van Bommel
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The antithrombotic management of atrial fibrillation
A novel user-friendly score (HAS-BLED) to assess 1-year
risk of major bleeding in patients with atrial fibrillation: the
Euro Heart Survey
Despite extensive use of oral anticoagulation (OAC) in patients
with atrial fibrillation (AF) and the increased bleeding risk
associated with such OAC use, no handy quantification tool
Fig 2 Example of a patient
with a significant improvement
in mitral regurgitation 6 months
after cardiac resynchronization
therapy. At baseline, the MR jet
area exceeded 80 % of the left
atrium area and the effective
regurgitant orifice area (EROA)
was 0.61 cm2 (Panels A
[4-chamber view] and B
[parasternal long-axis view]).
At 6-month follow-up, the jet
area decreased to 10 % of the
left atrium area and the EROA
was 0.19 cm2 (Panels C
[4-chamber view] and D
[parasternal long-axis view])
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for assessing this risk exists. We aimed to develop a practical
risk score to estimate the 1-year risk for major bleeding (intra-
cranial, hospitalisation, haemoglobin decrease>2 g/L, and/or
transfusion) in a cohort of real-world patients with AF. Based
on 3978 patients in the Euro Heart Survey onAFwith complete
follow-up, all univariate bleeding risk factors in this cohort
were used in a multivariate analysis along with historical bleed-
ing risk factors. A new bleeding risk score termed HAS-BLED
(Hypertension, Abnormal renal/liver function, Stroke, Bleeding
history or predisposition, Labile international normalised ratio,
Elderly (> 65 years), Drugs/alcohol concomitantly) was calcu-
lated, incorporating risk factors from the derivation cohort.
Fifty-three (1.5 %) major bleeds occurred during 1-year
follow-up. The annual bleeding rate increased with increasing
risk factors. The predictive accuracy in the overall population
using significant risk factors in the derivation cohort (C statistic
0.72) was consistent when applied in several subgroups. Ap-
plication of the new bleeding risk score (HAS-BLED) gave
similar C statistics except where patients were receiving
antiplatelet agents alone or no antithrombotic therapy, with C
statistics of 0.91 and 0.85, respectively. This simple, novel
bleeding risk score (HAS-BLED) provides a practical tool to
assess the individual bleeding risk of real-world patients with
AF, potentially supporting clinical decision-making regarding
antithrombotic therapy in patients with AF.
Clinical correlates of immediate success and outcome at 1-year
follow-up of real-world cardioversion of atrial fibrillation:
the Euro Heart Survey
In atrial fibrillation (AF) cardioversion is the cornerstone of the
rhythm management strategy despite the lack of contemporary
data on acute and long-term success. We aim to describe
present-day cardioversion of AF and identify characteristics
associated with immediate and long-term outcome. Based on
the 5333 AF patients enrolled in the multicentre prospective
Euro Heart Survey on AF we selected the 1801 patients under-
going cardioversion at enrolment. Sinus rhythm (SR) was
restored in 630 of 712 (88 %), 458 of 643 (71 %), and 333 of
446 (75 %) (P<0.001) of the electrical (ECV), intravenous
(ivCCV), and oral (oCCV) chemical cardioversions, respec-
tively, at the cost of few (4.2 %) major complications. In
multivariate analysis, absence of chronic obstructive pulmo-
nary disease (COPD) (P<0.001), presence of paroxysmal AF
(PAF) (P=0.013), and use of biphasic waveform (P=0.018)
were predictors of successful ECV. For ivCCVPAF (P<0.001),
absence of valvular heart disease (P=0.004), and heart failure
(P=0.009), the presence of hypertension (P=0.018) and
coronary artery disease (P=0.007) were predictive. Success of
oCCV was driven by PAF (P<0.001) and a smaller left atrial
dimension (P=0.001). At 1-year follow-up 893 of 1271 (70 %)
patients were in SR. Multivariate analysis revealed PAF (P<
0.001), shorter total AF history (P<0.001), continuous use of
Class Ic drugs or amiodarone during follow-up (P<0.001),
absence of COPD (P=0.003), younger age (P=0.004), and
smaller left atrial dimension (P=0.005) as independent pre-
dictors of SR at 1-year follow-up. Contemporary cardioversion
of AF is routinely successfully and safely performed with a
high proportion of patients in SR at 1-year follow-up.
Potential net clinical benefit of population-wide implementa-
tion of apixaban and dabigatran among European patients
with atrial fibrillation. A modelling analysis from the Euro
Heart Survey
Vitamin K antagonists (e.g. warfarin) are commonly
underutilised, due to limitations such as the need for monitor-
ing, in high-risk atrial fibrillation (AF) patients. We therefore
aimed to model the potential impact on clinical outcomes in
patients with AF with the use of the novel oral anticoagulant
(OAC) drugs, apixaban and dabigatran.We identified all high-
risk (CHA2DS2-VASc score ≥2) patients with non-valvular
AF and known 1-year follow-up from the Euro Heart Survey
on AF (EHS-AF). We modelled the expected numbers of
clinical events on the novel OACs using published hazard
ratios from their respective phase 3 clinical trials and calcu-
lated the numbers needed to treat and the mathematical net
clinical benefit. Our analysis included 3400 patients [39 %
females; mean (SD) age 67 (12) years; CHA2DS2-VASc score
3.0 (1.8)] of which 330 were excluded from the modelling
analysis due to concomitant use of OAC and antiplatelet
drugs. During 1-year follow-up, 108 (3.2 %) patients experi-
enced thromboembolism, 51 (1.5 %) major bleeds and 146
(4.3 %) died. Compared with current treatments (i.e. warfarin,
aspirin or nothing) the use of apixaban in high-risk patients
would have potentially prevented an additional 17 deaths, 27
strokes and eight major bleeds within this cohort. With the use
of dabigatran 150 mg twice daily (bid), 34 strokes could have
been prevented and for dabigatran 110 mg bid, 16 strokes and
six major bleeds would be avoided. Extrapolation of the data
from the EHS-AF to the whole of Europe would translate into
the prevention of an additional 64,573 major cardiovascular
events and deaths each year among patients with a CHA2DS2-
VASc ≥2, by the use of apixaban, 43,235 by the use of
dabigatran 150 mg bid and 27,272 by the use of dabigatran
110 mg bid. In conclusion, based on this modelling exercise,
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the utilisation of apixaban and dabigatran for thrombo-
prophylaxis could provide a profound annual mathematical
net clinical benefit on stroke and major bleeds in European AF
patients.
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